
... BIBLIOGRAPHY ...

- Allison DB, Pannarites JC, Zinner DE, et al. An obesity cost of illness model. Presented November 10, 1997, NAASO Annual Conference, Cancun, Mexico.
- American Diabetes Association. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. *Diabetes Care* 1997;20:1183-1203.
- American Journal of Health System Pharmacy. FDA proposes constraints on ephedrine dietary supplements (news). *Am J Health Syst Pharm* 1997;54:1578
- Arch JR, Wilson S. Prospects for beta 3-adrenoceptor agonists in the treatment of obesity and diabetes. *Int J Obes Relat Metab Disord* 1996;20:191-199.
- Atkinson RL, Hubbard VS. Report on the NIH Workshop on Pharmacologic Treatment of Obesity. *Am J Clin Nutr* 1994;60:153-156.
- Bertera R. The effects of workplace health promotion on absenteeism and employment costs in a large industrial population. *Am J Public Health* 1990;80:1101-1105.
- Blair SN, Kohl HW, Paffenbarger RS, et al. Physical fitness and all-cause mortality: A prospective study of healthy men and women. *JAMA* 1989;262:2395-2401.
- Blundell JE, Hill AJ. Dexfenfluramine and appetite in humans. *Int J Obes* 1992;16 (Suppl 3):551-559.
- Brady W, Buss J, Moser R, et al. Defining total corporate health and safety costs: Significance and impact. *J Occup Med* 1997;38:224-231.
- Brownell KD, Marlatt GA, Lichtenstein E, Wilson GT. Understanding and preventing relapse. *Am Psychol* 1986;41:765-782.
- Brownell KD, Rodin J. Medical, metabolic, and psychological effects of weight cycling. *Arch Intern Med* 1994;154:1325-1330.
- Drent ML, Larsson I, William-Olsson T, et al. Orlistat (Ro 18-0647), a lipase inhibitor, in the treatment of human obesity: A multiple dose study. *Int J Obes* 1995;19:221-226.
- Edington DW, Yen LT, Witting P. The financial impact of changes in personal health practices. *J Occup Med* 1997;39:1037-1046.
- Erfurt JC, Foote A, Heirich MA. The cost-effectiveness of work-site wellness programs for hypertension control, weight loss, and smoking cessation. *J Occup Med* 1991;33:962-970.
- Fairburn CG. *Overcoming Binge Eating*. New York: Guilford Press; 1995.
- Fontaine KR, Cheskin LJ, Barofsky, I. Health-related quality of life in obese persons seeking treatment. *J Fam Pract* 1996;43:265-270
- Goldstein DJ, Rampey AH Jr, Enas GG, et al. Fluoxetine: A randomized clinical trial in the treatment of obesity. *Int J Obes Relat Metab Disord* 1994;18:129-135.
- Goldstein, DJ. Beneficial health effects of modest weight loss. *Int J Obesity* 1992;16:397-415.
- Gorskey R, Pamuk E, Williamson DF, Shaffer PA, Kaplan JP. The 25-year health care cost of women who remain overweight after 40 years of age. *Am J Prev Med* 1996;12:388-394.
- Guy-Grand B, Crepaldi G, Lefebvre P, et al. International trial of long-term dexfenfluramine in obesity. *Lancet* 1989;8672:1142-1144
- Huse DM, Oster G, Killen AR, et al. The economic costs of non-insulin dependent diabetes mellitus. *JAMA* 1989;262:2708-2713.
- Kato M, Shimazu M, Moriguchi S, Kishino Y. Body mass index (BMI) is a reliable index to estimate obesity as a risk factor for deteriorating health. *Tokushima J Exp Med* 1996;43:1-6.
- Kuczmarski RJ, Flegal KM, Campbell SM, Johnson CL. Increasing prevalence of overweight among US adults: The National Health and Nutrition Examination Surveys (NHANES), 1960-1991. *JAMA* 1994;272:205-211.
- Lean ME. Sibutramine: A review of clinical efficacy. *Int J Obes Relat Metab Disord* 1997;21 (Suppl 1):S30-S36.
- Lew EA, Garfinkel L. Variations in mortality by weight among 750,000 men and women. *J Chron Dis* 1979;32:563-576
- Marie V, Dupuy F, Bazin R. Acute injection of beta-adrenoceptor agonist BRL 35135 corrects both impaired uncoupling protein and lipoprotein lipase gene expression but not hypercapacity of lipogenesis in brown adipose tissue of suckling fa/fa rats. *Int J Obes Relat Metab Disord* 1994;18:273-279.
- McCann UD, Seiden LS, Rubin LJ, et al. Brain serotonin neurotoxicity and primary pulmonary hypertension from fenfluramine and dexfenfluramine: A systematic review of the evidence. *JAMA* 1997;278:666-672.
- NIH Technology Assessment Conference Panel. Methods for voluntary weight loss and control. NIH Technology Assessment Conference Panel. Consensus Development Conference. *Ann Intern Med* 1993;119:764-770.
- Pelletier KR. A review and analysis of the health and cost-effective outcome studies of comprehensive health

... BIBLIOGRAPHY ...

- promotion and disease prevention programs. *Am J Health Promot* 1991;5:311-315.
- Prochaska JO, DiClemente CC, Norcross JC. In search of how people change: Applications to addictive behaviors. *Am Psychol* 1992;117:1102-1114.
 - Pelletier KR. A review and analysis of the health and cost-effective outcome studies of comprehensive health promotion and disease prevention programs at the work-site: 1991-1993 update. *Am J Health Promot* 1993;8:50-62.
 - Pelletier KR. A review and analysis of the health and cost-effective outcome studies of comprehensive health promotion and disease prevention programs at the work-site: 1993-1995 update. *Am J Health Promot* 1996;10:380-388.
 - Quesenberry CP, Caan B, Jacobson A. Obesity, health services utilization, and health care costs among members of a health maintenance organization. *Arch Intern Med* 1998 (in press).
 - Rabkin SW, Chen Y, Leiter L, Liu L, Reeder BA. Risk factor correlates of body mass index. Canadian Heart Health Surveys Research Group. *CMAJ* 1997;157 (Suppl 1):S26-S31.
 - Rohner-Jeanrenaud F, Cusin I, Sainsbury A, et al. The loop system between neuropeptide Y and leptin in normal and obese rodents. *Horm Metab Res* 1996;28:642-648.
 - Rundall TG, Schauffler HH. Health Promotion and Disease Prevention in Integrated Delivery Systems: The role of market forces. *Am J Prev Med* 1997;12:244-250.
 - Stock MJ. Sibutramine: A review of the pharmacology of a novel anti-obesity agent. *Int J Obes Relat Metab Disord* 1997;21 (Suppl 1):S25-S29.
 - Weintraub M, Sundaresan PR, Madan M, et al. Long-term weight control study. *Clin Pharmacol Ther* 1992;51:586-619.
 - Whitmer RW, Dundon MW. The Health Enhancement Research Organization (HERO). *Am J Health Promot* 1997;11:388-393.
 - Wolf AM, Colditz G. Current estimates of the economic cost of obesity in the United States. *Obesity Res* 1998 (in press).
 - Zhi J, Melia AT, Koss-Twardy SG, et al. The influence of orlistat on the pharmacokinetics and pharmacodynamics of glyburide in healthy volunteers. *J Clin Pharmacol* 1995;35:1103-1108.